Institutional brokerage houses released critical rating actions and target revisions on Friday, September 18, 2026, tracking eight major corporate counters across diverse sectors including energy, ports, infrastructure, healthcare, NBFCs, pharmaceuticals, and retail. Market sentiment remains decisively tilted in favor of quality capital goods, logistics, and renewable energy conglomerates, with leading international research firms recommending a "Buy" or "Outperform" stance on seven high-profile equities. Meanwhile, cautious consumer perspectives prompted a lone "Reduce" downgrade on retail supermarket operator Avenue Supermarts. The marquee recommendations prominently feature three Adani Group entities, alongside heavyweight infrastructure bellwether Larsen & Toubro and specialized healthcare and pharmaceutical innovators.

High Conviction Bets: Jefferies Backs Adani Trio, L&T, While Bernstein Champions Zydus Life

Jefferies maintained strong institutional backing across Adani Group counters, issuing a "Buy" rating on Adani Green Energy with a target price of ₹1,695. The brokerage noted management's steady trajectory to commission 5 GW of fresh green power in FY27, backed by synchronized grid transmission links that insulate assets from grid curtailment, alongside scaling battery energy storage systems (BESS) from 3.6 GWh to beyond 10 GWh. On Adani Ports and Special Economic Zone, Jefferies retained a "Buy" call with a target of ₹2,150, evaluating management’s vision to cross 1 billion tonnes in cargo throughput by 2030, which could flip the balance sheet into a net-cash position by FY31. For Adani Power, the firm set a "Buy" target of ₹270, highlighting its 45 GW capacity roadmap by FY32 where 56 percent of the pipeline is secured through long-term power purchase agreements (PPAs), projecting a 22 percent EBITDA CAGR between FY26 and FY30. Engineering conglomerate Larsen & Toubro (L&T) also garnered a "Buy" rating from Jefferies with a ₹5,000 target, citing sustained domestic and Middle Eastern capital expenditure orders that insulate its 10–12 percent FY27 revenue growth trajectory against regional geopolitical uncertainties. In the pharmaceutical space, Bernstein initiated an "Outperform" call on Zydus Life with a target of ₹1,457, pointing out that Novartis's recent clinical withdrawal of ALS candidate VHB937 on September 16 significantly eliminates competitive hurdles for Zydus's proprietary drug Usnoflast.

Sector Growth vs Headwinds: Medanta and M&M Finance Upbeat as DMart Faces Margin Scrutiny

Expanding coverage across high-margin tertiary healthcare, Investec initiated a "Buy" rating on Global Health (Medanta) with a price target of ₹1,730, projecting steady mid-to-high single-digit gains in average revenue per operating bed (ARPOB) and capitalizing on planned footprint expansions beyond its core NCR base, culminating in doubled bed capacity beyond FY29. On non-banking financial lender Mahindra & Mahindra Financial Services, CLSA retained an "Outperform" recommendation with a price target of ₹425, commending the financier’s ability to defend net interest margins (NIMs), sustain return on assets (RoA) above 2.2 percent over three consecutive quarters, and extract cross-selling fee income from insurance distribution despite marginal agricultural asset quality risks linked to erratic climate patterns. In stark contrast to the broader bullish consensus, HSBC issued a "Reduce" stance on Avenue Supermarts (DMart) with a revised target price of ₹3,520 per share. The global bank observed that although DMart maintains essential price advantages—undercutting rapid-delivery online platforms by 5 percent via DMart Ready and by 10 percent in physical supermarket aisles—its heavy retail store footprint additions in non-metro urban pockets face acute operational execution risks and rising competitive saturation.